



Corporate Update

APRIL 2019



STRICTLY CONFIDENTIAL

This presentation has been prepared by Cardiex Limited, (Cardiex or the Company), solely for its use in discussions between the Company and potential investors. The information contained in this presentation is an overview and does not contain all information necessary to make investment decisions. Although reasonable care has been taken to ensure that facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation, expressed or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this presentation and no reliance should be placed on such information or opinions. This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial advice nor take into consideration your investment objectives.

This presentation contains or may contain forward-looking statements that are based on management's belief, assumptions and expectations and on information currently available to management. All statements that are not historical, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements. Although management believes these forward-looking statements are fair and reasonable you should not place undue reliance on these statements.

INTRODUCTION

CardieX Limited



CRAIG COOPER – CEO

Australia

Co-Founder – NRG Asia–Pacific (Australia’s largest independent energy producer)

Founder – Private Energy Partners (PEP)

Partner – M-Mobile (largest independent mobile retail distribution company in Australia)

Senior Associate Lawyer – Blake Dawson Waldron – counsel to United Airlines, The Disney Corporation, DHL International (External General Legal Counsel)

“Craig has built and transformed some of the leading businesses in consumer Internet and digital media. He has a vision for big market opportunities and a passion for living life to the fullest.”

Anthony Robbins | Entrepreneur, Author and Peak Performance Strategist

USA

Co-Founder – Boost Mobile USA

Managing Partner – The Action Fund

Investor – The Huffington Post (acquired by AOL), BuzzFeed (USD\$3B), Buddy Media (acquired by Salesforce), Associated Content (acquired by Yahoo), xAD (USD\$1B)

TV Host & Investor – CNBC’s “Adventure Capitalists”

Head of Venture Capital and Digital Media – Saban Capital (USD\$700M)

Founding Partner – Softbank Capital (USD\$500M)

Venture Partner – VantagePoint Capital Partners (USD\$3B)

Co-Founder – EBT Mobile (China) LTD



BOARD OF DIRECTORS



Chairman (Interim)
Niall Cairns

BEC, ACA, FAICD

Managing Partner - Kestrel Capital Pty Limited
Chairman - Tambla Limited (ASX:TBL)
Director - Chant West Holdings Limited (ASX:CWL)
Director - Carbine Agri-Investment Limited
(formerly Tru-Test Corporation Limited)
Managing Partner - Kestrel Growth Funds
Managing Partner - Carnethy Evergreen Fund



Executive Director & CEO
Craig R. Cooper

BEC, LLB (Hons)



Non-Executive Director
R. King Nelson

BA, MBA

Director - Regenesys Biomedical
President, CEO & Director - Uptake Medical
Director - Digirad (NASDAQ:DRAD)
President, CEO & Director - Kerberos Proximal Solutions
President, CEO & Director - VenPro Medical (Medtronic)
Division President - Baxter Healthcare (various businesses)
Sales & Marketing - American Hospital Supply

KEY MANAGEMENT



Doug Kurschinski
EVP & Head of Global Sales

Cardiac Pathways (Boston Scientific)
St Jude Medical (Abbott)
Stereotaxis



Jarrod White
Chief Financial Officer

Traverse Accountants
University of Sydney



ZiHan Lin
VP of Corporate Development

Masimo
Uptake Medical
Harvard / Stanford



Harry Kim
Senior Advisor

American Well
Samsung Electronics
Hewlett Packard
Deloitte Consulting



Rhonda Welch
Strategic Market Access

J&J - Biosense Webster
Baxter Healthcare



Lawrence Chan
Director of Product Development


Cochlear
Silverbrook Research




Ahmad Qasem
Principal Scientist



PhD in Biomedical Engineering
Macquarie University

CORPORATE HISTORY





*Co-development/
engineering office with
Blumio, Inc



BUSINESS OVERVIEW

Gold Standard Medical Technology + Wearable &
AI Solution + Consumer & Digital Telehealth



BUSINESS OVERVIEW


We provide digital and device-based solutions for large-scale population health disorders with significant market scale.

- Current focus is **cardiovascular disease (CVD) and heart health** - the #1 cause of premature death globally.
- Our long-term future lies in developing large-scale health technologies in other significant global wellness markets (e.g. obesity, orthopedic health, diabetes management, urology).

Our health solutions and IP have the potential to disrupt multiple multi-billion dollar markets in preventative diagnostics, patient management, wearables, and consumer/digital health.



We provide investment exposure to 3 of the fastest growing global healthcare market opportunities.



OUR MISSION IS
TO CREATE A
SIGNIFICANT AND
VALUABLE
HEALTHCARE
ECOSYSTEM OF
COMPLIMENTARY
PRODUCTS AND
SERVICES




THE PROBLEM

A Global Health Epidemic

Cardiovascular disease is the **#1 killer of humans** by non-natural causes.

- Over **1 billion** hypertensive individuals globally.
- **20M** deaths per year from CVD-related disorders (28% of all global deaths).
- **45%** of American adults are now considered at risk for CVD according to New American Heart Association (AHA) guidelines.
- Current embedded technologies (brachial blood pressure cuff) are failing to properly detect, prevent, and manage heart disease - leading to significant under- and over-treatment.

WE NEED A BETTER WAY TO DETECT CVD AND MANAGE PATIENT HEALTH OUTCOMES.



OUR SOLUTIONS

Medical Devices - AtCor

Significant Intellectual Property and Clinically Proven Technology.

Our **XCEL SphygmoCor®** system allows specialist practitioners, pharmaceutical companies, as well as research institutions to **non-invasively measure central arterial pressure** in patients.

- Measuring central arterial pressure is the only non-invasive way to accurately determine pre-hypertension and arterial stiffness - the main precursors to key organ damage and cardiovascular disease.
- The system is able to detect key parameters associated with CVD that are usually only detected with an invasive catheter.
- The only **FDA 510(k)-cleared and Medicare-reimbursed** device for sale in the USA deemed to be substantially equivalent to an invasive catheter for all central measurements.

Over
1000
peer-reviewed
studies

Over
4400
installations
worldwide



 **Uniquely
Competitive**

 **FDA
Cleared**

 **Proprietary
Technology**

THE POWER OF CENTRAL PRESSURES

AtCor Advances Management by **Individualizing Therapy Approach**



Traditional blood pressures are measured with a pressure cuff on the upper arm

Central blood pressures are blood pressures at the ascending aorta that directly impact vital organs. Our algorithms use **pulse waveform analysis** to calculate **central pressures and arterial stiffness**, which scientific research has demonstrated to be **independently predictive** of CVD and other chronic diseases.

AtCor 
SphygmoCor Inside

What is the significance?

Combining central blood pressures with brachial blood pressures uncovers patient-specific insights that enable **individualized hypertension management** paradigm that accelerates patients reaching target blood pressures.

Central Pressures + Arterial Stiffness = Individualized Hypertension Management

OUR TECHNOLOGY

& Intellectual Property

- Gold standard **FDA-cleared** device for the measurement of central blood pressure and cardiovascular risk parameters (Standard FDA “predicate device”).
- Current IP and technology focused on cardiovascular health.
- Significant trademarks in consumer and wearable sectors.
- Future applications in “Quantified Athlete”, remote patient monitoring, and broad health categories.
- Proprietary IP & technology in cardiac load, athletic capacity, arterial stiffness, arterial age, and other consumer health diagnostic parameters.
- Expanding licensing and co-development opportunities in broad medical and consumer health segments.
- **Over 1000 published peer-reviewed studies.**
- 13 USA patents covering significant applications in cardiovascular health and consumer wearables.

1939

Hypertension

1961

Elevated
Cholesterol

TODAY

Arterial
Stiffness
PWV



Pulse Wave Velocity

(PWV) is the most research supported method to assess arterial stiffness in order to improve cardiovascular risk prediction (American Heart Association, American College of Cardiology). **CardieX's XCEL** is the the most clinically validated, peer viewed, and study based technology for measuring PWV.

OUR SOLUTIONS Cont.

Wearable Technologies - Blumio

Strategic and Financial Partnership to Develop Consumer-Focused Wearable Technologies for Cardiovascular Health Based on CardieX IP for central BP algorithms and Blumio IP for advanced BP sensing. Silicon Valley-based engineering and development team.

- Backed by Thiel Foundation (founded by Peter Thiel - PayPal co-founder and first investor in Facebook).
- Developer of specialized radar frequency sensors for cardiovascular disease, hypertension, and health monitoring.
- First phase trial completed at Macquarie University, and larger scale trial at Deborah Heart and Lung Center (USA) commenced in November 2018.
- Deborah site continues to successfully collect reference blood pressure data from subjects. Trial will continue until enough relevant data are extracted to allow for algorithms refinement, which is the ultimate goal of the larger scale study.
- Targeting ambulatory blood pressure monitoring opportunity - USD\$8B annual global market.

blumio



SEPARATELY PURSUING

Confidential wearable and licensing technology partnerships with multiple parties.

OUR SOLUTIONS Cont.

TeleHealth Services – inHealth

Leading Virtual Health Coaching and Telehealth Services Provider in USA.

- Providing digital, e-commerce and mobile tools for patients to connect online with health coaches as part of a patient care management program.
- Offering coaching programs based on multi-year published studies showing clinically significant health outcomes through use of inHealth’s proprietary health coaching tools.
- Serving a USD\$25B industry in the USA – growing at a compound rate of 18% per annum.
- Executing significant contracts with Anthem (NYSE:ANTM, USD\$70B), the second largest health insurance company in the USA, and American Well, the largest telemedicine provider in the USA.
- Adding significant value to the CardieX ecosystem.

Provides “**direct-to-consumer**” and “**direct-to-practitioner**” channel for CardieX products and services as well as new healthcare initiatives (wearables, medical devices, and digital health).



(see 'Transaction Overview' and more details below)

HOW WE CURRENTLY GENERATE REVENUE

We Sell/Lease XCEL SphygmoCor and Related Products to:



Research and Pharmaceutical companies for clinical trial services related to CVD and hypertension.



Specialist practices—principally Cardiologists, Nephrologists and Endocrinologists for measurement of **pulse wave** and cBP (central blood pressure).



IDN/health care service providers in the USA for sale to their affiliate hospital and caregiver networks.



Licensing agreement with SunTech Medical for 24-hour Ambulatory Blood Pressure Measurement (ABPM) for Oscar 2 SphygmoCor® device.

\$4M

6

Continents

34

Countries

4000+

Installations

FUTURE REVENUE DRIVERS

Multiple Revenue Opportunities Driven by Ecosystem of Complementary Healthcare Assets & Sales Channels



Medical Devices

- Sale and lease of medical devices to health professionals.
- Clinical trial services.
- IP licensing (SunTech).
- Distribution partnership fees (Asia-Pacific, China, and Europe).
- Direct/online device sales.



Wearable Consumer and Medical Technologies

- IP licensing.
- "Reference design" sales to wearable and consumer device companies (Apple/Fitbit/Garmin).
- Direct product sales of CardieX cardiovascular health wearables.
- Co-development revenues from jointly developed Blumio/CardieX products and IP.



Digital and Consumer Health

- Patient health coaching fees (Anthem/American Well etc).
- Consumer health product sales.
- Sale of nutritional and health coaching programs (devices, meal plans, supplements).
- "Direct to patient" consumer program sales.
- "Direct to practitioner" program sales.
- inHealth program licensing to wearable and consumer health companies (Apple/Fitbit/Garmin).
- Mobile app sales.



New Product Development

- Commercial in confidence development of new products and services for USA and Chinese medical and consumer markets.
- Current focus on commercialization of CardieX IP in new devices and technologies.

A blurred photograph of a crowd of people walking through a modern, brightly lit interior space, possibly a transit hub or office lobby. The image is overlaid with a semi-transparent blue filter. A white diagonal line cuts across the bottom right corner of the image.

OUR 2019 PLAN

Three new growth, product and revenue platforms + new China strategy

DIRECT-TO-PRACTITIONER

- Newly rebranded and **customizable** XCEL SphygmoCor® (V.2) allowing sales to multiple markets (consumer/health practitioner/specialist) with a single product at variable price points.
- Expanding our core technology and products to a broader health practitioner market (1M+ licensed MDs and 30K naturopathic professionals in the USA), representing a 30x increase in our current addressable market.
- Enabling health practitioners to create new significant revenue streams (turning a **non-billable** event into a **billable event** by using our CPT1 Medicare reimbursement code).
- Leveraging direct-to-practitioner marketing and training using online and direct sales channels.
- Continuing sales focus built around a multi-platform health management + lifestyle program w/ CardieX App.
- Expanding CPT reimbursement program from (current) 46% USA coverage.



\$5B Total Addressable Market Opportunity

30,000
Specialists
(Cardiologists, Nephrologists)

1M+
MDs/Licensed Health Practitioners

↑↑↑↑↑↑↑↑↑↑↑↑↑↑↑↑
30X in our addressable sales market



WEARABLES AND DEVICES

blumio

- Co-developing wearable blood pressure sensor, incorporating AI and CardieX IP, for a USD\$7.5B global market opportunity.
- Developing suite of AI-powered consumer - targeted features for licensing to device manufacturers/OEMs (i.e. Apple), such as “cardiac load” and “exercise capacity”.
- Co-developing wearable 24-hour ambulatory BP monitor (ABPM).

USD\$8B+
Global Market Opportunity



CONSUMER & DIGITAL HEALTH

- Enabling consumers to directly manage their health through **direct-to-consumer** digital products, patient health coaching, and technologies that drive **behavioral change** (target market - over 1 billion hypertensive individuals globally).
- Expanding the inHealth telehealth programs to encompass solutions for hypertension and other major global health disorders.
- Establishing OEM partnerships for branded consumer blood pressure monitoring devices.
- Currently in due diligence on multiple strategic opportunities.

1B Hypertensives
Globally



At home blood pressure monitoring expected to reach

USD\$1.6B

globally by 2023 (IEEE)

CHINA MARKET DEVELOPMENT

Continued Growth in Hospitals and Expansion into Telemedicine and Consumer Health

Hospital Market

Strengthen clinical marketing of central BP and arterial stiffness across various specialties

Establish OEM partnerships with vital sign monitor manufacturers to integrate AtCor technology

Telemedicine Market

Focus on supplying clinically validated telehealth services and home health devices onto telemedicine platforms

Consumer Market

Focus consumer education efforts on the dangers of arterial stiffness

Establish technology partnerships with smart wearables makers and home BP monitor manufacturers to integrate AtCor technology



PROGRESS ON KEY INITIATIVES

Rapidly Progressing on Multiple Focus Areas

AtCor 

blümio

inHealth
medical services

CHINA 



- Significantly expanding Bayer contract by ~50% to support international heart failure trial covering more than 70 participating sites.
- Launching API-based OEM strategy targeting patient monitors, ambulatory blood pressure monitors, home blood pressure monitors and smart wearables.
- Sales tracking internal plan for FY19.



- Deborah trial in New Jersey progressing to cover additional care areas to increase patient enrollment.
- Initial validation trials successfully completed, proving out data output by Blumio sensor comparable to that of radial tonometer, the gold standard in measuring arterial stiffness and blood pressure waveform.
- Validation represents critical milestone for central blood pressure reference design under CardieX-Blumio JDA, and results to be presented at IEEE Body Sensor Networks conference in May.

- Anthem telehealth revenues on plan through March 2019, and revenue forecast for FY19 revised upward.
- Initiating sleep health collaboration with global electronic and medical device company (GEMDC) with initial focus on chronic sleep disorders.
- Launching hypertension pilot trial – first consumer trial to demonstrate superior patient outcome with combined teleahealth coaching and SphygmoCor assessment.
- Preparing for diabetes management pilot trial with Kaiswer Permanente.

- Launching CardieX China operating company – sales and technical staff recruitment progressing.
- Multiple SphygmoCor OEM partnerships under discussion with NDAs executed.
- Machine learning-powered individualized hypertension management collaboration with major Chinese AI company under discussion.
- Piloting inHealth telehealth services through major Chinese telemedicine platform with ~140M patient interactions to date.

KEY HIGHLIGHT

AtCor XCEL

Gold Standard Medical Technology for Hypertension
and CVD Management



THE FUTURE: ATCOR *EVERYWHERE*


Flexible Integration Options to Maximize Adoption of Proprietary APIs



Cloud-Based




Onboard Software



Embedded Chip

INTEGRATION PROCESS



Technical
Feasibility



Empirical
Testing



Verification &
Validation



Commercial
Launch

DRIVEN BY OUR PROPRIETARY APIs

Comprehensive Portfolio for OEMs across the Full Digital Spectrum



MEDX
API

Vital Sign Monitors

- Ejection Duration
- Augmentation Index
- Reference Age
- Mean Arterial Pressure
- Heart Rate
- Reflection Magnitude
- Pulse Pressure Amplification
- Buckberg SEVR
- Central Pulse Pressure
- Central BP - Systolic/Diastolic

API Options

- Fully Customizable
- Uniquely Competitive
- Openly Compatible

- Heart Rate
- Augmentation Index
- Reference Age
- Buckberg SEVR
- Central BP - Systolic/Diastolic
- Pulse Pressure Amplification
- Central Pulse Pressure
- Mean Arterial Pressure
- Ejection Duration
- Reflection Magnitude



HEALTHX
API

Smart Wearable

- Cardiac Load
- Heart Rate
- Exercise Capacity
- Reference Age



HOMEX
API

Ambulatory & Home BPM

- Central Pulse Pressure
- Pulse Pressure Amplification
- Heart Rate
- Exercise Capacity
- Cardiac Load
- Reference Age

MEDX API

For Vital Sign Monitors

- For outpatient spot-check use
- Target care areas in hospital: **Cardiology, Nephrology, Endocrinology, Hypertension Clinic**
- Our most full-featured API with a comprehensive suite of proprietary central BP and arterial stiffness capabilities


INTEGRATION OPTIONS



Cloud-Based



Onboard Software



Embedded Chip



FEATURES

- Augmentation Index
- Buckberg SEVR
- Reference Age
- Heart Rate
- Central Systolic Pressure
- Central Diastolic Pressure
- Central Pulse Pressure
- Pulse Pressure Amplification
- Mean Arterial Pressure
- Ejection Duration
- Reflection Magnitude

HOMEX API

For Ambulatory & Home BP Monitors

- For non-hospital on-demand spot-check use
- Target devices: **ambulatory BP monitors and home-use BP monitors**
- Our mid-tier API featuring clinically useful and consumer-friendly central BP and arterial stiffness measurements


INTEGRATION OPTIONS



Cloud-Based



Onboard Software



Embedded Chip



FEATURES

- Cardiac Load
- Exercise Capacity
- Vascular Age
- Heart Rate
- BPX Central Systolic Pressure
- BPX Central Diastolic Pressure
- CVD Risk Score

HEALTHX API

For Smart Wearable Devices

- For daily use (continuous monitoring)
- Target wearables: **smart bands, smartwatches, smart earbuds**
- General health measurements related to arterial stiffness and cardiovascular function


INTEGRATION OPTIONS



Cloud-Based



Onboard Software



Embedded Chip



FEATURES

- Cardiac Load
- Vascular Age
- Exercise Capacity
- Heart Rate



OUR API AND
PRODUCT STRATEGY
IS TARGETED
TOWARDS TAKING
CARDIEX FROM
"THE GROUND TO
THE CLOUD"



KEY HIGHLIGHT

Blumio

Wearable Blood Pressure & AI Solution

PARTNERSHIP WITH BLUMIO

Co-Development of Next Generation Wearable Diagnostics

Strategic and financial partnership focused on developing wearable technologies for consumer-focused cardiovascular health based on the central BP algorithm IP from CardieX/AtCor and advanced BP sensing IP from Blumio.

- Silicon Valley-based engineering and development team.
- Backed by Thiel Foundation (founded by Peter Thiel - PayPal co-founder and first investor in Facebook).
- Developer of specialized radar frequency sensors for cardiovascular disease, hypertension, and health monitoring.
- First phase trial completed at Macquarie University, and larger scale trial at Deborah Heart and Lung Center (USA) commenced in November 2018.
- Deborah continues to successfully collect reference blood pressure data from subjects. Trial will continue until enough data is collected to allow refinement of our algorithms, which is ultimate goal of the study.

USD\$ 10B MARKET OPPORTUNITY



SEPARATELY PURSUING

Confidential wearable and licensing technology partnerships with multiple parties.

THE OPPORTUNITY



7ⁱⁿ10

USA adults track
a health indicator
for themselves or a
loved one

(PEW)



88%

Of physicians
want patients to
monitor their health
parameters at home

(IDC)



87%

Reduction in
readmissions with
remote patient
monitoring

GROWING DEMAND FOR NON-INVASIVE CONTINUOUS PHYSIOLOGICAL SENSORS

MARKET OPPORTUNITY

USD\$8.5B+



Arrhythmia
(ZIO)

USD\$1.5B Mkt Cap

MARKET OPPORTUNITY

USD\$12B+



Continuous Blood
Glucose Monitoring
(Dexcom)

USD\$5.2B Mkt Cap

MARKET OPPORTUNITY

USD\$8B+



Blood Pressure and
Heart Diagnostics
(CardieX)

\$\$\$B Mkt Cap

SIGNIFICANT USE CASES FOR SENSOR-BASED CARDIAC MONITORING

- Home and ambulatory BP monitoring for 1B hypertensive individuals globally.
- Peripheral arterial disease management - 20% of humans over 60 years old.
- Continuous blood pressure monitoring - 592,000 patients in American hospitals every day.
- Wrist wearables - 58 million units annually.

Smart “wristbands”
volume expected to reach


52M

by 2021 (IDC)



SENSOR/WEARABLE REVENUE POTENTIAL

- Ambulatory blood pressure monitoring (ABPM) - USD\$8 billion per year
- Hardware OEM - USD\$540M per year
- IP Licensing - USD\$300M per year



CARDIEX CONSUMER WEARABLE APPLICATIONS

- CardieX has significant proprietary IP and data in a number of unique consumer health applications - "cardiac risk", "cardiac load", and "exercise capacity".
- IP licensing as part of the sale of a "sensor stack" to Blumio.
- Third-party IP licensing to Apple, Fitbit, and other OEMs.
- Successful initial trials in partnership with Blumio and Macquarie University , and now larger-scale trial ongoing at Deborah Heart & Lung Center in New Jersey.

Our consumer IP and wearable applications have the potential to significantly increase human performance and personal data analytics.



New Fast Track FDA
Certification Process for
Digital Health Apps



// The Blumio sensor uses radar technology in combination with sophisticated signal processing. An important distinguishing feature of the Blumio sensor is that it is essentially contactless, thus increasing its potential applications. //

Alberto Avolio, BE, PhD (UNSW), FIAMBE

Professor of Biomedical Engineering

The Australian School of Advanced Medicine @ Macquarie University

Former Chairman, Pulse of Asia International Symposium

KEY HIGHLIGHT

inHealth

Leading Digital & Consumer Telehealth Platform



INHEALTH

Business & Market Overview

- Leading provider of digital patient health coaching and Telehealth services.
- Provides digital, eCommerce, and mobile tools for patients to connect online with health coaches as part of a patient care management program.
- inHealth's programs based on multi-year published studies that show clinically based health outcomes through the use of inHealth's proprietary health management tools.
- Telehealth solutions being accelerated Nationwide by hospitals (over 50% of US hospitals are currently deploying Telehealth), insurance payers (Anthem), employers, and through direct-to-patient platforms (American Well).
- Telehealth also rapidly being integrated across devices that provide Patient Generated Health Data ("PGHD" - Fitbit/Apple Watch/ home health devices such as blood pressure monitors).
- Telehealth seen as a critical part of the next generation healthcare ecosystem in order to reduce insurance payer costs and drive better health outcomes for patients.




Aubrey Jenkins
CEO and Co-Founder



Michelle Alencar
CSO and Co-Founder

11 Fulltime Employees, 35 Active + 170 (pre-screened) Telehealth Coaches

Telehealth Size & Growth Rate



HEALTH COACHING IS THE MISSING LINK IN THE HEALTHCARE CHAIN

Any device that "mines" patient generated health data ("PGHD") requires a Telehealth solution.

Data Mining Devices

- zzz Fitbit (Sleep & Weight Loss)
- Garmin (Stress)
- ZIO (Arrhythmia)
- Blumio (Blood pressure)
- AtCor XCEL (Blood pressure)
- Apple Watch (EKG)
- Dexcom (Diabetes)



Telehealth Coaching

inHealth provides the crucial link between data and diagnostics, and better patient outcomes.



Connected Devices

- Amazon Alexa
- Google Home
- Apple HomePod

Apple logo
"Hey Siri, how can I lose weight?"


Amazon logo
"Alexa how can I reduce my blood sugar?"

INHEALTH CUSTOMIZED PROGRAMS

Designed to Drive Provider Revenue and Help Patients Meet Health Goals

Weight Loss Management

Nine different multidisciplinary Weight Loss programs focusing on Nutrition, Behavior and Fitness - all supported by inHealth-certified coaches.



Diabetes Prevention

inHealth-certified diabetes prevention dietitians and programs that comply with CDC's DPP standards.



Sports Nutrition

inHealth-certified protocols for maximum performance and diet analysis services that include complete sports analysis.



LAUNCHING 2019

Hypertension Management

Evidence-based protocols combined with inHealth-certified coaches help users stay accountable and bring about significant blood pressure reductions safely.



LAUNCHING 2019

Sleep Health

Lifestyle intervention with weight management support from inHealth-certified coaches to improve sleep quality - from sleep hygiene to obstructive sleep apnea.



LAUNCHING 2019


Mental Health

inHealth-certified clinicians help patients address psychological factors that can be tied to chronic diseases, such as depression or anxiety.



Chronic Care Management (CCM)

For Medicare beneficiaries who have multiple chronic conditions.



ACQUISITION OF INHEALTH MEDICAL

Transaction Overview

A strategic and value add transaction that multiplies the value of the CardieX Group assets and business operations.

- Acquisition of 50.5% of an established "direct-to-patient" online health platform with leading insurance groups, health professionals, and corporate/employer payer groups as existing customers.
- Transaction provides for CardieX to gain operational and financial control through a series of staged investments through 2020.
- Direct relationships with Fortune 500 companies and leading companies in the USA healthcare ecosystem.
- Multi-year contracts with significant USA healthcare companies driving accelerated revenue growth (Anthem (#2 USA health insurance company - US\$74B) & American Well (#1 USA Telemedicine platform).
- Major business and corporate deal pipeline with leading companies in consumer goods, pharmaceutical companies, and healthcare providers.
- Value driven acquisition forecast to contribute to CardieX revenue and profitability in a short time frame - inHealth revenues growing strongly and forecast to become profitable in 2019.
- inHealth business model based on immediate multi-tier revenue structures in one of the fastest growing health technology sectors.
- Strong synergy with CardieX existing business operations.


SAMPLE INHEALTH PROGRAMS

inHealth programs are designed to empower providers, drive practice revenue, & help patients meet their health goals.



CURRENT CUSTOMERS

Corporate Telehealth Business Pipeline*



*via American Well partnership.

Plus > 2M DTC Enrollments

INHEALTH KEY BUSINESS OPERATING SEGMENTS



```
graph LR; A((INHEALTH KEY BUSINESS OPERATING SEGMENTS)) --- B((INSURANCE PAYERS)); A --- C((TELEMEDICINE PROVIDERS)); A --- D((CORPORATE WELLNESS PROGRAMS)); A --- E((PRIVATE PRACTICE)); A --- F((DIRECT TO PATIENT));
```

**INSURANCE
PAYERS**

**TELEMEDICINE
PROVIDERS**

**CORPORATE
WELLNESS
PROGRAMS**

**PRIVATE
PRACTICE**


**DIRECT TO
PATIENT**

STRATEGIC VALUE

of inHealth to CardieX Group

- Strongly positions CardieX in the high growth digital and consumer Telehealth sector.
- Provides CardieX's core technology with direct channels to both the consumer, health insurance, and practitioner markets.
- Positions CardieX (via inHealth) with leading US health insurance companies and healthcare providers with multi-year contracts (Anthem & American Well) - each of which have stated strong growth intentions for the respective partnerships.
- Provides a platform for the development and sale of insurance backed technology solutions covering multiple health disorders (e.g. heart health, hypertension, sleep) that can be sold through inHealth's existing insurance and partner network and business pipeline.

"Any device or platform in the future that provides personal health generated data ("PHGD") will require a Telehealth component in order to maximize patient outcomes"



Our vision is to build the largest global Telehealth company with multiple product and service offerings across the healthcare sector. inHealth is our platform for executing this vision.

- Creates an "in-house" clinical trial group within CardieX that can cost effectively run and manage clinical trials for CardieX group products.
- Key executive "C suite" relationships across the chain of the US healthcare system.
- An existing suite of proprietary healthcare products and services that can be rapidly deployed into the corporate wellness sector as well as across multiple global markets including, and as a priority, China.
- A direct and online channel for sale of CardieX group products (Blumio wearable technology and CardieX's XCEL device).
- Partnership opportunities to provide turnkey Telehealth management programs to the next generation of healthcare providers that need patient care services including Apple (Apple Health "click to connect"), Alibaba and SoftBank (recently announced health platforms), Amazon (Alexa Health), and Google (Health Services Group).

KEY HIGHLIGHT


China

Fast-Tracking Product & Market Development




STAGGERING FIGURES FROM CHINA

Hypertension Leads to Numerous Chronic Conditions



Significant increase of Chinese clinical publications on Central Blood Pressure and Arterial Stiffness using SphygmoCor technology in last 15 years

Clinical Publications




*Shanghai Key Laboratory of Hypertension @ Ruijin Hospital

CURRENT ATCOR USERS IN CHINA



Approved

Trusted by Top Tier Medical Institutions Across the Country



LEVERAGING AI IN THE CHINESE MARKET

Enriching the Largest Wearables Market on the Planet

623k

Daily inpatient visits
in China requiring BP
monitoring

680M

Hypertensive and
pre-hypertensive
in China

43%

Urban Chinese
consumers own
wearable devices

50M

Annual shipment of
wearable devices in
China

1

Financial & strategic
partnership to co-
develop wearables that
can detect hypertension,
CVD and other health
disorders.

2

Integrate AI analytics
into smart wearable
devices.


3

Incorporate CardieX IP
and trademarks into
proprietary consumer
applications for health
and fitness.

Our
Wearables
Solution

TOP SECRET

**COMMERCIAL IN-CONFIDENCE
PRODUCT AND CHINESE MARKET
DEVELOPMENT PROCEEDING RAPIDLY
WITH FURTHER ANNOUNCEMENTS
THROUGHOUT Q2-Q4 2019**



THANK YOU

CONTACT

Craig Cooper
CEO - CardieX
ccooper@cardiex.com
0429 993 399

